2025-02-02 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Report

**0. Key Figures Overview:**

VRTX's cumulative return significantly outperforms the S&P 500 (VOO) by 42.5 percentage points.  Technical indicators suggest strong momentum, but high RSI levels hint at potential overbought conditions. Recent earnings show some volatility, but generally strong revenue growth and high profit margins.

**1. Performance Comparison & Company Overview:**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for cystic fibrosis and other genetic diseases.

* **Cumulative Return (VRTX):** 162.38%
* **Cumulative Return (VOO):** 119.91%
* **Return Difference:** 42.5%
* **Relative Outperformance:** 67.9% (based on historical range)

The provided alpha and beta analysis across different years shows a generally positive alpha (outperformance relative to the market) and varying beta (market sensitivity).  The high CAGR (Compound Annual Growth Rate) in several periods points towards strong growth potential.  Noteworthy is the significant negative alpha observed in 2019-2021, indicating underperformance relative to the market during that period. Market capitalization (Cap(B)) exhibits consistent growth.

**2. Recent Price Movement:**

* **Closing Price:** $461.68
* **5-Day Moving Average:** $445.23
* **20-Day Moving Average:** $424.75
* **60-Day Moving Average:** $446.79

The stock price shows a recent increase, currently trading above its 5-day and 20-day moving averages, suggesting short-term upward momentum.  The price is slightly above the 60-day moving average, indicating relatively sustained bullish trends.  The significant daily price change of $5.31 (Last-market data) signifies a strong upward movement â€“ a rapid increase (rapid uptrend).

**3. Technical Indicators and Expected Return:**

* **RSI:** 81.40 (Overbought territory; potential for correction)
* **PPO:** 1.19 (Positive; bullish momentum)
* **20-Day Relative Strength Change:** +9.3% (Short-term upward momentum)
* **Expected Return (Long-term):** 18.7% (Outperformance compared to S&P 500 over 2+ years)

The high RSI value suggests the stock might be overbought and prone to a near-term correction.  The positive PPO confirms the bullish momentum. The significant positive change in relative strength (Delta_Previous_Relative_Divergence) supports the short-term bullish outlook.  The expected return highlights a significant long-term outperformance potential.

**4. Recent Earnings Analysis:**

| Date       | EPS     | Revenue     | Notes                                         |
|------------|---------|-------------|----------------------------------------------|
| 2024-11-05 | $4.05   | $2.77B      |                                              |
| 2024-08-02 | -$13.92 | $2.65B      | Significant negative EPS; investigate cause   |
| 2024-05-07 | $4.26   | $2.69B      |                                              |
| 2023-11-07 | $4.01   | $2.48B      |                                              |
| 2024-11-05 | $4.01   | $2.48B      | Possible data duplication; needs clarification |

The earnings data shows significant volatility, particularly the large negative EPS in August 2024. Further investigation is needed to understand the reasons behind this outlier.  Revenue shows consistent growth overall. The duplicated entry for November 2024 needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin | Notes                                     |
|---------|----------|---------------|------------------------------------------|
| 2024-09-30 | $2.77B  | 85.84%       |                                          |
| 2024-06-30 | $2.65B  | 85.94%       |                                          |
| 2024-03-31 | $2.69B  | 87.27%       |                                          |
| 2023-12-31 | $2.52B  | 85.38%       |                                          |
| 2023-09-30 | $2.48B  | 87.17%       |                                          |

Revenue shows a steady upward trend. Profit margins remain consistently high, indicating strong profitability.


**Capital and Profitability:**

| Quarter | Equity    | ROE       | Notes                               |
|---------|-----------|------------|------------------------------------|
| 2024-09-30 | $15.63B  | 6.69%     |                                    |
| 2024-06-30 | $14.77B  | -24.32%   | Significantly negative ROE; investigate |
| 2024-03-31 | $18.55B  | 5.93%     |                                    |
| 2023-12-31 | $17.58B  | 5.51%     |                                    |
| 2023-09-30 | $16.51B  | 6.27%     |                                    |

Equity fluctuates, and ROE shows a significant negative value in Q2 2024. This needs further investigation to determine the underlying causes.

**6. Overall Analysis:**

VRTX exhibits strong long-term growth potential, significantly outperforming the S&P 500.  However, recent earnings data reveals some volatility that needs further analysis.  The high RSI suggests a potential short-term correction is possible.  The substantial recent price increase warrants caution.  Investors should monitor the factors behind the Q2 2024 negative ROE and the August 2024 negative EPS before making investment decisions.  Despite these concerns, the long-term outlook remains positive, particularly given the consistently high profit margins and expected long-term outperformance.  Further research into the reasons for the recent volatility is crucial.
